An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
PHASE2
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea ...
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
PHASE2
Clinical Indication : HER mutated or HER2 Amplification/Overexpression in G...
Status
Withdrawn
Location
Yonsei University Health System, Severance Hospital
Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer
PHASE2
This is an open-label, non-randomised, phase II study to evaluate the effic...